Tuszynski, H. M., Thal, L., Pay, M., Salmon, P. D., Sang U, H., Bakay, R., Patel, P., Blesch, A., Vahlsing, L. H., Ho, G., Tong, G., Potkin, G. S., Fallon, J., Hansen, L., Mufson, J. L., Kor-dower, H. J., Gall, C. and Conner, J. (2005) A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer dis-ease. Nat. Med. 11, 551–555.

has been cited by the following article:

• TITLE: Review: structure of amyloid fibril in diseases

  AUTHORS: Arezou Ghahghaei, Nasim Faridi

  KEYWORDS: Amyloid; Protofilaments; Aggregation; Neurodegenerative

  JOURNAL NAME: Journal of Biomedical Science and Engineering, Vol.2 No.5, September 17, 2009

  ABSTRACT: Tissue deposition of normally soluble proteins, or their fragments, as insoluble amyloid fibrils causes both acquired and hereditary systemic amyloidoses, which is usually fatal. Amyloid is associated with serious diseases such as Alz-heimer’s disease, type 2 diabetes, Parkinson’s Disease, Huntington’s Disease, cancer and the transmissible spongiform encephalopathies. In-formation concerning the structure and mecha-nism of formation of fibrils in these diseases is critical for understanding the process of pathol-ogy of the amyloidoses and to the development of more effective therapeutic agents that target the underlying disease mechanisms. Structural models have been made using information from a wide variety of techniques, including electron microscopy, X-ray diffraction, solid state NMR, and Congo red and CD spectroscopy. Although each type of amyloidosis is characterised by a specific amyloid fibril protein, the deposits share pathognomonic histochemical properties and the structural morphology of all amyloid fibrils is very similar. In fact, the structural similarity that defines amyloid fibres exists principally at the level of β-sheet folding of the polypeptides within the protofilament, while the different types vary in the supramolecular assembly of their proto-filaments.